B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
AMLX
AmylyxFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bullish case is that completed LUCIDITY enrollment de-risks execution, prior avexitide studies showed statistically significant hypoglycemia reductions, and the reported cash runway into 2028 gives AMLX enough time to reach its main value-defining readout without obvious immediate financing stress [#8-K-2026-03-24] [#10-K-2026-03-03].
Posture
Defensive
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-10-27.
What can break
AMLX remains heavily dependent on a successful Phase 3 avexitide outcome, making the setup binary despite multiple programs.
Momentum
73
Value
41
Sentiment
14
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $17.00 · Bull $24.00 · Bear $9.50Analysis 2026-04-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $43.00
Why
Momentum73 · Δ7d -11.3
Value41 · Δ7d -0.0
Sentiment14 · Δ7d -1.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-27.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • AMLX remains heavily dependent on a successful Phase 3 avexitide outcome, making the setup binary despite multiple programs.
- • Low external coverage and sparse visible analyst data reduce confidence in consensus valuation and revision signals.
- • The bear case is that AMLX remains largely a clinical-outcome story with valuation concentrated on avexitide's Phase 3 result; failure to reproduce prior signal strength, regulatory delay around follow-on programs, or faster-than-expected cash burn could compress the stock sharply.
Catalyst clock
2026-09-30
Avexitide Phase 3 LUCIDITY topline data in Q3 2026
Lead driver: Value · See fundamentals
Momentum
73
8% active weight
Current posture
7d trendSoftening
Δ7d
-11.3
Δ21d
-13.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
14
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.9
Δ21d
-1.0
Why this grade
Composite grade F. Momentum 72.8 / Value 40.6 / Sentiment 13.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-29. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$3.4B
Beta
-0.30
Shares Out
125.51M
P/E (TTM) · Derived
-17.7
P/S (TTM)
3249.71
P/FCF (TTM) · Derived
-22.63
Rev YoY
-100.0%
EPS YoY
-16.0%
Gross Margin
-94.5%
Op Margin
-47349.8%
Net Debt
-$311.02M
Current Ratio
12.12
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data